Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088229 | 0.81 | — | — | |
| SCHEMBL19254779 | 0.79 | — | — | |
| SCHEMBL12783044 | 0.79 | — | — | |
| SCHEMBL15976412 | 0.79 | SMN1; SMN2 (0.60) | POLBHTTNPC1SMN1; SMN2 | |
| SCHEMBL3573585 | 0.78 | — | — | |
| SCHEMBL1669260 | 0.78 | — | — | |
| SCHEMBL12341587 | 0.78 | NLRP3 (0.45) | — | |
| SCHEMBL19518740 | 0.78 | NLRP3 (0.45) | — | |
| SCHEMBL15279125 | 0.75 | MMP1 (0.47) | SMN1; SMN2 | |
| SCHEMBL23169663 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384639-B2 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384639-B2 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070231839-A1 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule or antibodies that immunospecifically bind a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070231839-A1 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule or antibodies that immunospecifically bind a gram-negative bacterial autoinducer molecule | UNIVERSITY OF ROCHESTER (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231839-A1 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule or antibodies that immunospecifically bind a gram-negative bacterial autoinducer molecule | C1R, C3AR1, C5AR1 | POLB 4409/4885HTT 3594/4885NPC1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.